• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Avita Medical Inc. (Amendment)

    2/9/23 11:07:47 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care
    Get the next $RCEL alert in real time by email
    SC 13G/A 1 tv0356-avitamedicalinc.htm SCHEDULE 13G/A avitamedicalinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 2)*

    Name of issuer:  Avita Medical Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  05380C102

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  05380C102

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    0

    7.  SOLE DISPOSITIVE POWER

    1,138,592

    8.  SHARED DISPOSITIVE POWER

    9,734

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,148,326

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.59%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Avita Medical Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    28159 Avenue Stanford, Suite 220
    Valencia, CA 91355

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    05380C102

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $RCEL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RCEL

    DatePrice TargetRatingAnalyst
    12/24/2024$25.00Buy
    D. Boral Capital
    4/11/2024Buy → Neutral
    BTIG Research
    6/27/2023$23.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $RCEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mcnamara Robert bought $91,300 worth of shares (11,000 units at $8.30), increasing direct ownership by 24% to 56,749 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      3/10/25 4:30:06 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • Director Mcnamara Robert bought $100,900 worth of shares (10,000 units at $10.09), increasing direct ownership by 28% to 45,749 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      2/20/25 4:30:19 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • CFO O'Toole David D bought $9,900 worth of shares (1,000 units at $9.90), increasing direct ownership by 4% to 25,734 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      2/20/25 4:30:08 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AVITA Medical Reports First Quarter 2025 Financial Results

      VALENCIA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights and Recent Developments Commercial revenue of $18.5 million, an increase of approximately 67% compared to the same period in 2024Gross profit margin of 84.7%In February, launched RECELL GO mini™, designed to treat smaller wounds, targeting U.S. trauma centers treating a high volume of small-area woundsOn April 1, initiated nationwide launch of Cohealyx™, an AVITA Medical-branded collagen-based d

      5/8/25 4:03:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • AVITA Medical to Host Acute Wound Care Showcase on May 13, 2025

      VALENCIA, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will host its inaugural Acute Wound Care Showcase 2025 on Tuesday, May 13, 2025, via webcast at 11:00 a.m. Pacific Time. The event will feature presentations from Jim Corbett, Chief Executive Officer, and Dr. Katie Bush, Senior Vice President of Scientific and Medical Affairs. The Acute Wound Care Showcase will provide an overview of AVITA Medical's comprehensive approach to acute wound care. Attendees joining the webcast will gain insights into the company's product portfolio, includi

      4/24/25 9:00:00 AM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • AVITA Medical to Announce First Quarter 2025 Financial Results

      VALENCIA, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound company delivering transformative solutions, today announced that it will report its first quarter 2025 financial results after the close of the U.S. financial markets on Thursday, May 8, 2025. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, May 9, 2025, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights. The live webcast will be accessible under the Events & Presentations section of the AVITA Medical website at ir.avitamedical.com. To participate by

      4/17/25 4:05:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mcnamara Robert bought $91,300 worth of shares (11,000 units at $8.30), increasing direct ownership by 24% to 56,749 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      3/10/25 4:30:06 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • Director Mcnamara Robert bought $100,900 worth of shares (10,000 units at $10.09), increasing direct ownership by 28% to 45,749 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      2/20/25 4:30:19 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • CFO O'Toole David D bought $9,900 worth of shares (1,000 units at $9.90), increasing direct ownership by 4% to 25,734 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      2/20/25 4:30:08 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital initiated coverage on Avita Medical with a new price target

      D. Boral Capital initiated coverage of Avita Medical with a rating of Buy and set a new price target of $25.00

      12/24/24 7:10:27 AM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • Avita Medical downgraded by BTIG Research

      BTIG Research downgraded Avita Medical from Buy to Neutral

      4/11/24 7:58:22 AM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • Cantor Fitzgerald initiated coverage on Avita Medical with a new price target

      Cantor Fitzgerald initiated coverage of Avita Medical with a rating of Overweight and set a new price target of $23.00

      6/27/23 7:26:40 AM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    Financials

    Live finance-specific insights

    See more
    • AVITA Medical Reports First Quarter 2025 Financial Results

      VALENCIA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights and Recent Developments Commercial revenue of $18.5 million, an increase of approximately 67% compared to the same period in 2024Gross profit margin of 84.7%In February, launched RECELL GO mini™, designed to treat smaller wounds, targeting U.S. trauma centers treating a high volume of small-area woundsOn April 1, initiated nationwide launch of Cohealyx™, an AVITA Medical-branded collagen-based d

      5/8/25 4:03:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • AVITA Medical to Announce First Quarter 2025 Financial Results

      VALENCIA, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound company delivering transformative solutions, today announced that it will report its first quarter 2025 financial results after the close of the U.S. financial markets on Thursday, May 8, 2025. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, May 9, 2025, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights. The live webcast will be accessible under the Events & Presentations section of the AVITA Medical website at ir.avitamedical.com. To participate by

      4/17/25 4:05:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • AVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results

      VALENCIA, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights and Recent Business Updates Commercial revenue of $18.4 million, an increase of approximately 30% compared to the same period in 2023Gross profit margin of 87.6%On December 19, 2024, the FDA granted 510(k) clearance for Cohealyx™, an AVITA Medical-branded collagen-based dermal matrixOn December 23, 2024, the FDA approved RECELL GO® miniOn February 13, 2025, amended the credit

      2/13/25 4:01:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    Leadership Updates

    Live Leadership Updates

    See more
    • AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary

      VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024. Ms. Kelsey has more than two decades of executive legal experience with expertise in M&A, securities, and governance, along with a strong track record building and leading global regulatory and compliance programs. Previously, she served as Chief Legal Officer and Secretary for Amyris, Inc. (NASDAQ:AMRS) and General Counse

      7/1/24 4:05:00 PM ET
      $RCEL
      $AMRS
      Medical/Dental Instruments
      Health Care
      Major Chemicals
      Industrials
    • AVITA Medical Announces Appointment of David O'Toole as Chief Financial Officer

      VALENCIA, Calif. and MELBOURNE, Australia, June 15, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced the appointment of David O'Toole as its new Chief Financial Officer, effective June 15, 2023. O'Toole is an accomplished financial executive with more than 30 years of experience in global corporate finance, capital markets, and accounting across biotech and life sciences companies. He has a demonstrated track record of developing and executing successful growth strategies in a number of public

      6/15/23 4:05:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • AVITA Medical Appoints New Non-Executive Member to the Board of Directors

      VALENCIA, Calif. and MELBOURNE, Australia, March 23, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today the appointment of Robert McNamara to its Board of Directors, effective April 1, 2023. Mr. McNamara is an accomplished senior executive with over 25 years of leadership experience in public and privately held companies in the medical device and technology industries. His extensive experience in operations and financial management spans across early stage, high growth, and mature companies. He

      3/23/23 4:30:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Avita Medical Inc.

      SC 13G - AVITA Medical, Inc. (0001762303) (Subject)

      2/13/24 4:58:57 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Avita Medical Inc.

      SC 13G - AVITA Medical, Inc. (0001762303) (Subject)

      1/26/24 4:23:41 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Avita Medical Inc. (Amendment)

      SC 13G/A - AVITA Medical, Inc. (0001762303) (Subject)

      2/9/23 11:07:47 AM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    SEC Filings

    See more
    • SEC Form 10-Q filed by Avita Medical Inc.

      10-Q - AVITA Medical, Inc. (0001762303) (Filer)

      5/8/25 4:15:41 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • Avita Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AVITA Medical, Inc. (0001762303) (Filer)

      5/8/25 4:05:17 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Avita Medical Inc.

      DEF 14A - AVITA Medical, Inc. (0001762303) (Filer)

      4/22/25 4:30:18 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care